STAT+: Terns’ drug may not be as competitive as many initially thought
Why it matters: The competitive outlook for Terns' Duchenne drug impacts future treatment options for patients.
- Terns' drug for Duchenne may not be as competitive as initially believed, according to STAT+.
- Gilead continues its M&A streak, indicating ongoing consolidation within the biotech industry.
- A controversial class of drugs for Duchenne is under scrutiny, adding complexity to the therapeutic landscape for the disease.
Terns Pharmaceuticals' Duchenne drug is facing skepticism regarding its competitiveness, despite initial high expectations. This news comes amidst broader discussions in the biotech sector, including the controversial nature of certain Duchenne drug classes and Gilead's recent acquisition activities, as highlighted in The Readout.
